Trial Profile
Trastuzumab, docetaxel and gemcitabine as first line treatment for HER-2 positive advanced breast cancer: a phase II of G.O.I.M.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 11 Jul 2011 New trial record